Adam Hurewitz, MD Internal Medicine - Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 222 Station Plaza North, Suite 400, Mineola, NY 11501 Phone: 516-663-2834 Fax: 516-663-4696 |
Dr. Erin Kathleen Meier, MD Internal Medicine - Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 222 Station Plz N Ste 509, Mineola, NY 11501 Phone: 516-663-2381 Fax: 516-663-8796 |
Peter Spiegler, MD Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 222 Station Plaza North, Suite 400, Mineola, NY 11501 Phone: 516-663-2834 Fax: 516-663-4696 |
Aleksey Etinger, D.O. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 259 1st St, Mineola, NY 11501 Phone: 516-663-8963 Fax: 516-663-8964 |
Shalinee Chawla, MD Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 222 Station Plaza North, Suite 400, Mineola, NY 11501 Phone: 516-663-2834 Fax: 516-663-4696 |
Michael David Weinstein, MD Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 222 Station Plaza North, Suite 400, Mineola, NY 11501 Phone: 516-663-2834 Fax: 516-663-4696 |
News Archive
Today, the American Lung Association is launching its first monthly podcast series, called Lungcast.
A new study led by researchers at the UCLA Heart Transplant Program showed that one particular combination using tacrolimus (TAC or PrografĂ’ also known as FK506) had significant anti-rejection benefits for heart transplant patients over other combinations.
Tools for assisting organizations in their efforts to more accurately calculate, analyze, interpret and communicate the costs and benefits of workplace safety and health programs are featured as part of published proceedings released on July 29th in the National Safety Council's Journal of Safety Research (JSR).
Retrophin, Inc. today announced the completion of the previously announced acquisition of Manchester Pharmaceuticals LLC for a total of $62.5 million, including an upfront payment of $29.5 million, plus other payments based on product sales.
› Verified 3 days ago